ArticleBMC microbiology2025
Agglutination of yeast-binding antibodies from human blood plasma products.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYeasts are ubiquitous microorganisms found both endogenously within the human body and in the environment. Humoral responses against yeasts lead to the production of yeast-binding antibodies, which can agglutinate yeast cell targets. These antibodies affect the accuracy of immunodiagnostic tools employing yeast cells as in recombinant surface antigen display.
aimTo improve the applicability of such tools, the study aims to determine the abundance and characterize the agglutinating behavior of yeast-binding antibodies. METHODOLOGY: The study employed the use of a yeast agglutination assay to determine the prevalence of agglutination across human fresh frozen plasma samples (n = 36). The mean area of the agglutinin complex served as the basis for differentiating positive and negative samples. Indirect ELISA set-ups using protein A, protein G, and anti-IgM horseradish peroxidase conjugates were used to quantify titers and characterize the isotypes driving agglutination.
resultsThe results of the agglutination assays and indirect ELISA revealed that the formation of agglutinin complexes was promoted by a low pH and inhibited by a high ionic strength. Coagulation factors and complement proteins did not significantly contribute to agglutination. Finally, elution of agglutinating proteins was performed and the resulting eluate was tested further for re-binding and re-agglutination with yeast cells, suggesting the presence of antibodies.
conclusionFindings from the current study suggest that antibody-mediated yeast cell agglutination driven by immunoglobulins (i.e., IgM, IgG) present in human plasma can be affected by various physicochemical factors such as pH (i.e., acidity) and ionic strength (i.e., NaCl concentration) but is independent of the activity of coagulation factors. These conditions must be carefully optimized in the development of cell-based immunoassays and yeast surface display technologies, which utilize antibody-mediated yeast agglutination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.